Sham Mailankody
Clinical Director, Cellular Therapy Service · New York Presbyterian Hospital
Credentials: · · · ·
History
PresentCellular Therapy Service · New York Presbyterian Hospital
- Present
Myeloma Service · New York Presbyterian Hospital
- 2015–2017
- 2003–2007
Research
GPRC5D-Targeted CAR T Cells for Myeloma
New England Journal of Medicine · 2022 · First of 38 authors · 370 citations
The high price of anticancer drugs: origins, implications, barriers, solutions
Review · Nature Reviews Clinical Oncology · 2017 · Last of 3 authors · 310 citations
JAMA Internal Medicine · 2017 · 304 citations
- NK
93 papers · 2 as a fellow
78 papers
- AL
72 papers
- HH
66 papers
- MH
65 papers
- SG
62 papers
61 papers · 9 as a fellow
Saad Usmani
59 papers
Grants
- 2019–2022
National Cancer Institute · R21
PI · $429.7K · Sloan-Kettering Inst Can Research
Clinical trials
- 2023–2027
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
- 2022–2027
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
Principal investigator · Active not recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
- 2020–2027
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
Principal investigator · Active not recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
- 2018–2023
Short Course Daratumumab in Patients With Multiple Myeloma
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center